表紙：内分泌治療薬の2030年までの市場予測：治療領域、流通チャネル、投与経路、エンドユーザー、地域別の世界分析

市場調査レポート

商品コード

1383312

内分泌治療薬の2030年までの市場予測：治療領域、流通チャネル、投与経路、エンドユーザー、地域別の世界分析

Endocrinology Drugs Market Forecasts to 2030 - Global Analysis By Therapy Area, Distribution Channel, Route of Administration, End User and By Geography.

出版日: 2023年11月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 595,815円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 753,742円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 911,669円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,076,775円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、内分泌治療薬の世界市場は2023年に62億5,000万米ドルを占め、予測期間中にCAGR 14.3％で成長し、2030年には159億3,000万米ドルに達すると予測されています。

内分泌系医薬品は、内分泌系の機能を標的とし調整するように設計された医薬品物質です。これらの医薬品は、糖尿病、甲状腺疾患、副腎疾患、ホルモンバランスの乱れなど、幅広い内分泌疾患や症状の治療に使用されます。これらの薬剤は、特定の症状や関係するホルモンに応じて、経口薬、注射、局所治療などさまざまな形で投与されます。

国際糖尿病財団（IDF）の2021年最新版によると、2021年には約5億3,700万人の成人（20～79歳）が糖尿病とともに生活しています。

内分泌疾患の有病率の増加

内分泌疾患の有病率の増加は、内分泌治療薬市場の重要な促進要因です。座りがちな生活や食生活の乱れなどのライフスタイルの変化により、糖尿病や肥満などの疾患が増加しており、この両疾患の管理には内分泌治療薬が必要とされることが多いです。ホルモンバランスの乱れやそれに関連する疾病の増加は、内分泌かく乱物質への暴露などの環境要因に起因するものであるとの懸念が高まっています。さらに、こうした複合的な要因が内分泌治療薬に対する持続的な需要を生み出し、拡大する患者集団のニーズに対応する革新的な治療法を開発・販売する製薬企業の成長をもたらしています。

研究開発費

研究開発（R&D）コストは内分泌治療薬市場の大きな抑制要因です。新しい内分泌治療薬の開発には多額の財政投資が必要であり、多くの場合、長い年月と臨床試験にわたります。高額の研究開発費は、特に有望な医薬品が後期臨床試験で失敗した場合、製薬会社の財政負担につながる可能性があります。こうしたコストは薬価上昇の一因となり、ヘルスケア支払者や政府からの監視の目を集めることになります。厳格な安全性・有効性試験の必要性は、財政的負担をさらに増大させる。イノベーションの必要性と多額の研究開発費とのバランスをとることは困難な要因であり、製薬会社は競争の激しい内分泌市場において、潜在的な新薬候補を慎重に選択し、優先順位をつけることが不可欠です。

併用療法の開発

併用療法は内分泌学分野において有望な機会として浮上しており、さまざまな内分泌疾患の治療に潜在的な利益をもたらします。異なる薬剤や治療アプローチを組み合わせることで、併用療法は相乗効果をもたらし、治療成績や患者の奏効率を改善することができます。また、薬剤耐性などの問題に対処し、単一薬剤の大量投与に伴う副作用のリスクを軽減することもできます。さらに、併用療法は特定の疾患メカニズムや経路を同時に標的とする可能性があり、より包括的で個別化された治療戦略につながります。このアプローチは、糖尿病、甲状腺疾患、ホルモンバランスの乱れといった疾患の管理に特に関連しています。内分泌疾患の理解と新規治療薬の開発が進むにつれ、併用療法の探求と開発は、内分泌学における治療成果を最適化する重要な機会となっています。したがって、市場拡大には有利な成長が見込まれます。

規制上の課題

規制上の課題は、内分泌市場にとって大きな脅威となります。内分泌治療薬の開発、承認、商業化には、厳しく進化する規制が適用されます。FDAなどの規制機関は、安全性と有効性を確保するために厳格な基準を課しているため、承認までの期間が長期化し、コンプライアンスコストが高くなる可能性があります。これらの基準を遵守するためには多額の資金と人的資源が必要となるため、研究開発への投資が抑制される可能性があります。さらに、規制要件の変更は市場情勢に影響を与える可能性があり、常に適応する必要があります。したがって、こうした課題が市場の成長を妨げています。

COVID-19の影響

COVID-19の流行は内分泌治療薬市場に大きな影響を与えました。ヘルスケアシステムがウイルスの管理に注力した結果、内分泌疾患の診断と治療に混乱が生じた。さらに、サプライチェーンの混乱と医薬品不足は、内分泌治療薬の安定供給を維持する上での課題となっています。しかし、パンデミックは遠隔医療の普及を加速させ、遠隔モニタリングや処方管理の新たな道を提供しました。結局のところ、内分泌治療薬市場はパンデミックの間、遅延、医薬品不足、進化するヘルスケア・デリバリー・モデルといった複雑な状況に直面しました。

糖尿病治療薬セグメントは予測期間中最大となる見込み

糖尿病患者の増加、糖尿病治療薬の開発増加、糖尿病治療薬研究開発への投資増加により、糖尿病治療薬分野が最大のシェアを占めると推定されます。また、世界中で糖尿病の有病率が高く、糖尿病治療のための有望で効果的な医薬品が入手できないことも、このセグメントの成長に拍車をかけています。さらに、主要企業や政府機関による糖尿病治療薬開発への投資の増加は、このセグメントの成長を促進すると予想されます。したがって、糖尿病患者の増加と糖尿病治療薬開発のための研究資金の増加により、糖尿病セグメントは大きな成長を示すと予想されます。

病院薬局セグメントは予測期間中最も高いCAGRが見込まれる

病院薬局セグメントは予測期間中に有利な成長を遂げると予測されます。内分泌系医薬品は、ホルモンバランスの乱れや関連疾患に対処するために設計されています。このセグメントでは、病院薬局は重要な流通拠点として機能し、患者が適切な薬を管理されたタイムリーな方法で受け取れるようにします。また、患者教育においても重要な役割を果たし、内分泌治療薬の適切な使用法や潜在的な副作用について患者が理解できるよう支援しています。さらに、病院薬局は内分泌病専門医と協力し、複雑な薬物療法を伴うことが多い治療計画が効果的に実施されるようにします。従って、病院薬局は内分泌治療薬市場の重要な構成要素であり、患者の最適なケアと内分泌疾患の管理を促進しています。

最大のシェアを占める地域

北米は、内分泌疾患のリスクを増大させる高齢化人口の増加により、予測期間中に最大の市場シェアを獲得しました。糖尿病、インスリン抵抗性、甲状腺の問題を含む多くの内分泌疾患の発生率の増加は、米国とカナダにおける肥満症例の増加に起因しています。最も有病率の高い内分泌疾患である糖尿病は、有病率が高く、地域市場の収益に大きく貢献しています。さらに、米国糖尿病教育者協会（American Association of Diabetes Educators）や米国糖尿病協会（American Diabetes Association）などの団体が、この地域における患者教育分野の拡大を推進しています。

CAGRが最も高い地域：

アジア太平洋地域は、成長ホルモン欠乏症の有病率の上昇と、同地域における研究開発の成長が期待されることから、予測期間中に収益性の高い成長を遂げると予想されます。同地域の内分泌治療薬市場は、内分泌系に関連するがんや末期腎疾患を含む糖尿病の罹患率の増加から恩恵を受けると思われます。さらに、推定期間を通じて、更年期障害による性交疼痛症や外陰・膣萎縮症など、まれに発生する内分泌疾患に対する社会的認知度の高まりが、市場の成長を促進すると予想されます。また、内分泌疾患治療のための新薬や併用薬のイントロダクションなど、さまざまな研究パラダイムが実施されていることも、この地域の成長を後押しすると予想されます。

無料のカスタマイズ提供：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Abbott Laboratories,
Eli Lilly And Company
F. Hoffmann La Roche Ltd.
Novartis International AG
Pfizer Inc.
Alacer Corporation
Novo Nordisk A/S
Facet Biotech Corporation
Sanofi
Takeda Pharmaceutical Company Limited
Merck KGaA
AstraZeneca Plc
Lee Pharmaceuticals
MannKind
Acerus Pharmaceuticals Corp
Bayer AG
Endo International Plc
Beta Cell NV
Hanmi Pharm Co. Ltd
Ipsen Pharma

図表

List of Tables

Table 1 Global Endocrinology Drugs Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Endocrinology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
Table 3 Global Endocrinology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
Table 4 Global Endocrinology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
Table 5 Global Endocrinology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
Table 6 Global Endocrinology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
Table 7 Global Endocrinology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
Table 8 Global Endocrinology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
Table 9 Global Endocrinology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
Table 10 Global Endocrinology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
Table 11 Global Endocrinology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 12 Global Endocrinology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 13 Global Endocrinology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 14 Global Endocrinology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 15 Global Endocrinology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 16 Global Endocrinology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 17 Global Endocrinology Drugs Market Outlook, By Oral (2021-2030) ($MN)
Table 18 Global Endocrinology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
Table 19 Global Endocrinology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
Table 20 Global Endocrinology Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 21 Global Endocrinology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 22 Global Endocrinology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 23 Global Endocrinology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 24 North America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 25 North America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
Table 26 North America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
Table 27 North America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
Table 28 North America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
Table 29 North America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
Table 30 North America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
Table 31 North America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
Table 32 North America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
Table 33 North America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
Table 34 North America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 35 North America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 36 North America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 37 North America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 38 North America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 39 North America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 40 North America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
Table 41 North America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
Table 42 North America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
Table 43 North America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 44 North America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 45 North America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 46 North America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 47 Europe Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 48 Europe Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
Table 49 Europe Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
Table 50 Europe Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
Table 51 Europe Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
Table 52 Europe Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
Table 53 Europe Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
Table 54 Europe Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
Table 55 Europe Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
Table 56 Europe Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
Table 57 Europe Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 58 Europe Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 59 Europe Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 60 Europe Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 61 Europe Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 62 Europe Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 63 Europe Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
Table 64 Europe Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
Table 65 Europe Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
Table 66 Europe Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 67 Europe Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 68 Europe Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 69 Europe Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 70 Asia Pacific Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 71 Asia Pacific Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
Table 72 Asia Pacific Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
Table 73 Asia Pacific Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
Table 74 Asia Pacific Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
Table 75 Asia Pacific Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
Table 76 Asia Pacific Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
Table 77 Asia Pacific Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
Table 78 Asia Pacific Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
Table 79 Asia Pacific Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
Table 80 Asia Pacific Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 81 Asia Pacific Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 82 Asia Pacific Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 83 Asia Pacific Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 84 Asia Pacific Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 85 Asia Pacific Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 86 Asia Pacific Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
Table 87 Asia Pacific Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
Table 88 Asia Pacific Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
Table 89 Asia Pacific Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 90 Asia Pacific Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 91 Asia Pacific Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 92 Asia Pacific Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 93 South America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 94 South America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
Table 95 South America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
Table 96 South America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
Table 97 South America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
Table 98 South America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
Table 99 South America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
Table 100 South America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
Table 101 South America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
Table 102 South America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
Table 103 South America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 104 South America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 105 South America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 106 South America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 107 South America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 108 South America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 109 South America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
Table 110 South America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
Table 111 South America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
Table 112 South America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 113 South America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 114 South America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 115 South America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Table 116 Middle East & Africa Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 117 Middle East & Africa Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
Table 118 Middle East & Africa Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
Table 119 Middle East & Africa Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
Table 120 Middle East & Africa Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
Table 121 Middle East & Africa Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
Table 122 Middle East & Africa Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
Table 123 Middle East & Africa Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
Table 124 Middle East & Africa Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
Table 125 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
Table 126 Middle East & Africa Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 127 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 128 Middle East & Africa Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 129 Middle East & Africa Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 130 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 131 Middle East & Africa Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 132 Middle East & Africa Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
Table 133 Middle East & Africa Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
Table 134 Middle East & Africa Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
Table 135 Middle East & Africa Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 136 Middle East & Africa Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
Table 137 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 138 Middle East & Africa Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24162

According to Stratistics MRC, the Global Endocrinology Drugs Market is accounted for $6.25 billion in 2023 and is expected to reach $15.93 billion by 2030 growing at a CAGR of 14.3% during the forecast period. Endocrinology drugs are pharmaceutical substances designed to target and regulate the functions of the endocrine system. These drugs are used to treat a wide range of endocrine disorders and conditions, such as diabetes, thyroid disorders, adrenal gland disorders, and hormonal imbalances. These drugs can be administered in various forms, including oral medications, injections, and topical treatments, depending on the specific condition and the hormone involved.

According to the International Diabetic Foundation (IDF) 2021 update, approximately 537 million adults (20-79 years) were living with diabetes in 2021.

Market Dynamics:

Driver:

Growing prevalence of endocrine disorders

The growing prevalence of endocrine disorders is a significant driver of the endocrinology drug market. Lifestyle changes, including sedentary behaviour and poor dietary habits, have led to an increase in conditions like diabetes and obesity, both of which often require endocrinology medications for management. The increasing prevalence of hormonal imbalances and associated diseases has raised concerns and been attributed to environmental factors, such as exposure to endocrine-disrupting substances. Furthermore, these combined factors create a sustained demand for endocrinology drugs, providing growth for pharmaceutical companies to develop and market innovative treatments that address the needs of an expanding patient population.

Restraint:

Research and development costs

Research and Development (R&D) costs are a significant restraint in the endocrinology drugs market. Developing new endocrinology medications demands substantial financial investments, often spanning many years and clinical trials. High R&D expenditures can lead to financial strain for pharmaceutical companies, especially if promising drugs fail in late-stage trials. These costs contribute to elevated drug prices, attracting scrutiny from healthcare payers and governments. The need for rigorous safety and efficacy testing further increases the financial burden. Balancing the imperative for innovation with the substantial R&D expenses is a challenging restraint, making it essential for pharmaceutical firms to carefully select and prioritize potential drug candidates in the highly competitive endocrinology market.

Opportunity:

Development of combination therapies

Combination therapies have emerged as a promising opportunity in the field of endocrinology, offering potential benefits for the treatment of various endocrine disorders. By combining different drugs or treatment approaches, combination therapies can provide synergistic effects, improving treatment outcomes and patient response rates. They can also help address issues such as drug resistance and reduce the risk of adverse effects associated with high doses of a single medication. Moreover, combination therapies offer the potential to target specific disease mechanisms or pathways simultaneously, leading to more comprehensive and personalised treatment strategies. This approach is especially relevant in the management of conditions like diabetes, thyroid disorders, and hormonal imbalances. With ongoing advancements in understanding endocrine disorders and the development of novel therapeutic agents, the exploration and development of combination therapies present a significant opportunity to optimise treatment outcomes in endocrinology. Thus, there is lucrative growth for market expansion.

Threat:

Regulatory challenges

Regulatory challenges present a substantial threat to the endocrinology market. The development, approval, and commercialization of endocrinology drugs are subject to stringent and evolving regulations. Regulatory agencies, such as the FDA, impose rigorous standards to ensure safety and efficacy, which can lead to protracted approval timelines and high compliance costs. Compliance with these standards demands substantial financial and human resources, potentially discouraging investment in research and development. Additionally, changes in regulatory requirements can impact the market landscape, necessitating constant adaptation. Thus, these challenges are hampering market growth.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the endocrinology drugs market. The healthcare system's focus on managing the virus led to disruptions in the diagnosis and treatment of endocrine disorders. Additionally, supply chain disruptions and drug shortages posed challenges in maintaining a steady supply of endocrinology drugs. However, the pandemic also accelerated telehealth adoption, offering new avenues for remote monitoring and prescription management. Ultimately, the endocrinology drugs market faced a complex landscape of delays, drug shortages, and evolving healthcare delivery models during the pandemic.

The Diabetes Drugs segment is expected to be the largest during the forecast period

The Diabetes Drugs segment is estimated to hold the largest share, owing to the increase in cases of diabetes, the rise in the development of diabetic drugs, and the increase in investment in the development of diabetic drug research. Also, the high prevalence of diabetes across the globe and the unavailability of promising and effective drug products for the treatment of diabetes spurs the growth of this segment. Furthermore, a rise in investments in the development of diabetic drugs by key players or government agencies is expected to fuel the growth of the segment. Hence, due to the rise in cases of diabetes and the increase in research funding for the development of diabetic drugs, the diabetes segment is expected to witness significant growth.

The Hospital Pharmacies segment is expected to have the highest CAGR during the forecast period

The Hospital Pharmacies segment is anticipated to have lucrative growth during the forecast period. Endocrinology drugs are designed to address hormonal imbalances and related conditions. In this segment, hospital pharmacies serve as key distribution points; ensuring patients receive the right medications in a controlled and timely manner. They also play a pivotal role in patient education, helping individuals understand the proper use and potential side effects of endocrinology drugs. Moreover, hospital pharmacies collaborate with endocrinologists to ensure tailored treatment plans, often involving complex medication regimens, are effectively implemented. Hence, hospital pharmacies are vital components of the endocrinology drugs market, facilitating optimal patient care and management of endocrine disorders.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to the growing ageing population, which increases the risk of endocrine disorders. Increases in the incidence of a number of endocrine disorders, including diabetes, insulin resistance, and thyroid issues, can be attributed to the rise in obesity cases in the US and Canada. The most prevalent endocrine condition, diabetes, has a high prevalence and contributes significantly to regional market income. Moreover, the American Association of Diabetes Educators and the American Diabetes Association, among other groups, are driving the expansion of the patient education sector in the region.

Region with highest CAGR:

Asia- Pacific region is expected to witness profitable growth over the projection period, owing to a rise in the prevalence of growth hormone deficiency and the expected growth of research and development in the region. The market for endocrinology drugs in the area will benefit from an increase in the incidence of cancers related to the endocrine system and diabetes, including end-stage renal disease. Furthermore, throughout the duration of the estimated time frame, rising public awareness of infrequently occurring endocrine disorders-such as dyspareunia and vulvar and vaginal atrophy caused by menopause-is anticipated to fuel the market's growth. Various research paradigms carried out, such as the introduction of novel drugs and combination pharmaceuticals for the treatment of endocrine disorders, are also expected to boost the region's growth.

Key players in the market

Some of the key players in the Endocrinology Drugs Market include: Abbott Laboratories, Eli Lilly And Company, F. Hoffmann La Roche Ltd., Novartis International AG, Pfizer Inc., Alacer Corporation , Novo Nordisk A/S, Facet Biotech Corporation, Sanofi, Takeda Pharmaceutical Company Limited, Merck KGaA, AstraZeneca Plc, Lee Pharmaceuticals, MannKind, Acerus Pharmaceuticals Corp, Bayer AG, Endo International Plc, Beta Cell NV, Hanmi Pharm Co. Ltd and Ipsen Pharma.

Key Developments:

In March 2023, Eton Pharmaceuticals, a pharmaceutical company focused on developing and commercializing treatments for rare diseases, acquired a rare disease product candidate, ET-600, from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for treating an endocrinology condition estimated to impact less than 5,000 pediatric patients in the United States.

In February 2023, Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company, received approval from the Drug Controller-General of India (DCGI) for their product Lobeglitazone, an anti-diabetic drug. The drug is a new formulation manufactured specifically for type 2 diabetic patients by helping them improve pancreatic beta-cell function.

Therapy Areas Covered:

Diabetes Drugs
Growth Hormone Disorders
Thyroid Hormone Disorder Drugs
Testosterone Replacement Therapy
Osteoporosis
Adrenal insufficiency
Hypogonadism
Other Therapy Areas

Distribution Channels Covered:

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Other Distribution Channels

Route of Administrations Covered:

Oral
Transdermal
Injectable

End Users Covered:

Ambulatory Surgical Centers
Hospitals
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Endocrinology Drugs Market, By Therapy Area

5.1 Introduction
5.2 Diabetes Drugs
5.3 Growth Hormone Disorders
5.4 Thyroid Hormone Disorder Drugs
5.5 Testosterone Replacement Therapy
5.6 Osteoporosis
5.7 Adrenal insufficiency
5.8 Hypogonadism
5.9 Other Therapy Areas

6 Global Endocrinology Drugs Market, By Distribution Channel

6.1 Introduction
6.2 Hospital Pharmacies
6.3 Online Pharmacies
6.4 Retail Pharmacies
6.5 Other Distribution Channels

7 Global Endocrinology Drugs Market, By Route of Administration

7.1 Introduction
7.2 Oral
7.3 Transdermal
7.4 Injectable

8 Global Endocrinology Drugs Market, By End User

8.1 Introduction
8.2 Ambulatory Surgical Centers
8.3 Hospitals
8.4 Other End Users

9 Global Endocrinology Drugs Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Abbott Laboratories,
11.2 Eli Lilly And Company
11.3 F. Hoffmann La Roche Ltd.
11.4 Novartis International AG
11.5 Pfizer Inc.
11.6 Alacer Corporation
11.7 Novo Nordisk A/S
11.8 Facet Biotech Corporation
11.9 Sanofi
11.10 Takeda Pharmaceutical Company Limited
11.11 Merck KGaA
11.12 AstraZeneca Plc
11.13 Lee Pharmaceuticals
11.14 MannKind
11.15 Acerus Pharmaceuticals Corp
11.16 Bayer AG
11.17 Endo International Plc
11.18 Beta Cell NV
11.19 Hanmi Pharm Co. Ltd
11.20 Ipsen Pharma